TKNO — Alpha Teknova, Inc.

Is TKNO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Strong Oversold As of November 17, 2026

Alpha Teknova, Inc. (TKNO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $7.77. The rating moved from Neutral to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Alpha Teknova operates in an industry currently favored by growth flows, offering potential steady demand from research and biopharma customers. However, the lack of detailed recent filings in the provided data limits visibility into cash position, revenue cadence and margin trends, creating meaningful execution and financing uncertainty. Near-term drivers include R&D spending trends, specialty distribution shifts that can increase product flow to outpatient and biopharma channels, and general risk-on market sentiment supporting smaller growth names. Key downside scenarios include liquidity-driven dilution, operational disruptions, or a pullback in biopharma ordering. The outlook is balanced: modest upside exists if order momentum persists, but elevated event and financing risk warrants a cautious stance until clearer financials or catalyst-driven revenue inflection are confirmed.

Key factors

  • Market sentiment favors growth areas which may support demand for life-science/product suppliers in the near term.
  • Limited public financial filing analysis available in the provided dataset, creating uncertainty on balance sheet strength, cash runway and recent operating performance.
  • Exposure to life-science reagents / biopharma supply chains (readthrough from sector themes) could drive steady orders if R&D and biopharma commercialization activity remains healthy.
  • Moderate competitive pressure from larger suppliers and potential consolidation in distribution/specialty channels could compress margins over time.
  • Convertible/debt market dynamics in the sector increase the chance of future financing or dilution for mid/small-cap companies dependent on external capital.

Risks

  • Insufficient recent financial disclosure in the provided data increases uncertainty on liquidity, revenue trends and profitability.
  • High small-cap volatility and low trading liquidity can produce sharp price moves independent of fundamentals.
  • Risk of dilutive financing (convertible debt or equity raises) if cash runway is limited or if growth investments accelerate.
  • Customer concentration or reliance on a limited number of large biopharma clients could amplify revenue swings if orders shift.
  • Operational and supply-chain disruptions (raw materials, manufacturing scale) could impact delivery and margins.
  • Regulatory or quality-control issues in life-science manufacturing could materially affect reputation and sales.

See today's live rating, score and targets

Members see the live hourly rating for TKNO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.